Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Avidity Biosciences, Inc. (RNA) Accumulated Depreciation & Amortization (2019 - 2025)

Avidity Biosciences' Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $11.8 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 47.32% year-over-year to $11.8 million; the TTM value through Dec 2025 reached $11.8 million, up 47.32%, while the annual FY2025 figure was $11.8 million, 47.32% up from the prior year.
  • Accumulated Depreciation & Amortization reached $11.8 million in Q4 2025 per RNA's latest filing, up from $10.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $11.8 million in Q4 2025 to a low of $1.7 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $5.2 million, with a median of $4.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: dropped 12.43% in 2021, then skyrocketed 80.03% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.7 million in 2021, then skyrocketed by 80.03% to $3.1 million in 2022, then skyrocketed by 67.34% to $5.2 million in 2023, then soared by 53.17% to $8.0 million in 2024, then surged by 47.32% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Accumulated Depreciation & Amortization are $11.8 million (Q4 2025), $10.4 million (Q3 2025), and $9.6 million (Q2 2025).